Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
A Phase III study of Pfizer’s sigvotatug vedotin in non-small cell lung cancer missed a key overall survival target, according to market coverage on Tuesday. Pfizer said a larger subgroup showed survival trends that were more favorable than the standard chemotherapy comparator docetaxel.
THE APEX TIMES
THE APEX TIMES
The Federal Trade Commission says OptumRx and Emisar Pharma Services were involved in conduct it viewed as anticompetitive in insulin rebates, leading to a proposed settlement with UnitedHealth Group.
THE APEX TIMES
The retailer and pharmacy benefits giant said it joined local officials and colleagues to celebrate the opening of Mews at St. Mary, a new facility in Williamstown, NJ, in an event that also included a building dedication.
THE APEX TIMES
Sangamo Therapeutics said it has entered asset sale agreements with Eli Lilly and Astellas as it moves toward a voluntary Chapter 11 reorganization, aiming to maximize value for stakeholders during a structured auction process.
THE APEX TIMES
Investors reacted negatively after Pfizer said its lung cancer therapy, sigvotatug vedotin, did not significantly improve survival in a late-stage study, sending the stock lower on the day.
THE APEX TIMES
The companies say BioArctic will develop a new therapy candidate by pairing its BrainTransporter drug-delivery platform with a molecule from Lilly, aiming at targets in the neurodegenerative space.
THE APEX TIMES
A June 11 New York Times story pointed to two federal reports and raised questions about aspects of the healthcare system, sending CVS Health shares into focus for investors watching prescription-drug and care delivery costs.
THE APEX TIMES
The deal adds a new drug-delivery platform approach to Lilly’s pipeline, aiming to get therapies across the brain barrier for conditions classified under neurodegeneration.
THE APEX TIMES
In a market where GLP-1 and related obesity drugs are reshaping healthcare spending, Viking Therapeutics is positioning itself as a potential mid-cap challenger with the ambition to take market share from leaders including Eli Lilly and Novo Nordisk.
